Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Gov. Greg Abbott wants to create a new position in Texas—Chief State Prosecutor. The role, which would serve as a statewide ...

TheWrap spoke to several MS NOW staffers and executives about Rebecca Kutler’s first year as the network's president.

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

Polling in off-year election cycles is challenging because it’s hard to know who will turn out to vote. This year, the polls ...

Taking lipoic acid failed to ease progressive MS symptoms in a clinical trial, but the antioxidant showed signs of slowing ...

Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.

A member of a secret civil rights group that helped desegregate Bermuda at great personal risk in the late 1950s finds ...

An over-the-counter supplement called lipoic acid might help slow the loss of gray matter in the brains of people with ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.